bearish
SSI Weekly Newsletter: Updates on Liquidia, SpringWorks, Allakos, Acelyrin, SAGA, NZME, Nathan’s, HilleVax, TTEC
527 Views05 Apr 2025 17:00
Liquidia's NDA for Yutrepia accepted by FDA with a PDUFA date set for May 24, commercialization expected soon.
What is covered in the Full Insight:
- Portfolio Idea Updates
- Quick Pitch Updates
- Liquidia (LQDA) Commercialization
- SpringWorks (SWTX) Stock Reassessment
- Allakos (ALLK) Buyout Announcement
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Special Situation Investments
Event-Driven Investment Opportunities
Price Chart(Sign Up to Access)
- Loading...
x